Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy

Cancer Epidemiology
Luis Alberto Henríquez-HernándezLeandro Fernández-Pérez

Abstract

To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy. Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p=0.018) and 7.0 (95% confidence interval, 1.2-40.5; p=0.029), respectively). We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer.

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Nov 4, 1994·Science·S W LoweT Jacks
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J M Lee, A Bernstein
Oct 18, 2000·Molecular Cell Biology Research Communications : MCBRC·E N PapadakisD A Spandidos
Jun 14, 2002·Seminars in Oncology·Daniel F Hayes, Ann D Thor
Feb 5, 2003·Nature Genetics·Patrick DumontMaureen Murphy
Mar 6, 2003·Human Mutation·Anne-Lise Børresen-Dale
Mar 26, 2003·Endocrine-related Cancer·F Leonessa, R Clarke
Feb 24, 2004·American Journal of Epidemiology·Linda Sharp, Julian Little
Apr 14, 2005·Journal of Cellular Physiology·Antonio RussoViviana Bazan
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ye XuYuntao Xie
May 3, 2006·Human Molecular Genetics·Sharon Marsh, Howard L McLeod
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farin KamangarWilliam F Anderson
Jun 24, 2006·The Oncologist·Irina SachelarieRonald H Blum
Apr 3, 2007·Molecular Diagnosis & Therapy·Sharon Marsh
Oct 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon MarshRobert Brown
Oct 19, 2007·Cancer Research·Zuben E SaunaMichael M Gottesman
Nov 24, 2007·Pharmacogenomics·Marie-Christine Etienne-GrimaldiGérard Milano
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rohini SharmaStephen J Clarke
Jan 17, 2009·CA: a Cancer Journal for Clinicians·R Stephanie Huang, Mark J Ratain
May 26, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AfzalH E Poulsen
Nov 4, 2009·Oncology Reports·L A Henríquez-HernándezL Fernández Pérez

❮ Previous
Next ❯

Citations

Jun 5, 2013·European Journal of Cancer Care·B-B ZhangL-M Lun
Sep 13, 2016·International Journal of Molecular Sciences·Vid MlakarMarc Ansari
Oct 27, 2004·Critical Reviews in Oncology/hematology·Anis Feki, Irmgard Irminger-Finger
Nov 12, 2016·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Amir HossainMd Mustafizur Rahman
Dec 7, 2018·International Journal of Molecular Sciences·Yi-Chun ChenChiung-Mei Chen
Jun 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Filiz OzenOzturk Ozdemir
Aug 2, 2019·Pharmacogenomics·Gladys OliveraSalvador F Aliño
May 1, 2020·Frontiers in Pharmacology·Zeina N Al-MahayriBassam R Ali
Jun 27, 2019·International Journal of Surgical Pathology·Rui GuoJun Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved